Climb Bio, Inc. (CLYM)
| Market Cap | 515.90M +505.9% |
| Revenue (ttm) | n/a |
| Net Income | -52.79M |
| EPS | -0.79 |
| Shares Out | 47.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 655,215 |
| Open | 11.04 |
| Previous Close | 11.33 |
| Day's Range | 10.62 - 11.17 |
| 52-Week Range | 1.13 - 12.48 |
| Beta | 0.03 |
| Analysts | Strong Buy |
| Price Target | 18.83 (+74.35%) |
| Earnings Date | May 7, 2026 |
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for CLYM stock is "Strong Buy." The 12-month stock price target is $18.83, which is an increase of 74.35% from the latest price.
News
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, toda...
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, toda...
Climb Bio price target raised to $20 from $15 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $20 from $15 and keeps a Buy rating on the shares post the Q1 report.
Climb Bio price target raised to $17 from $15 at Wedbush
Wedbush raised the firm’s price target on Climb Bio (CLYM) to $17 from $15 and keeps an Outperform rating on the shares. With Climb Bio recently convening its R&D Spotlight…
Climb Bio reports Q1 EPS (20c), consensus (31c)
“During the first quarter, we continued to execute on a focused development strategy aimed at generating clear clinical and translational data across our two programs,” said Aoife Brennan, President a...
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER...
Climb Bio price target raised to $21 from $12 at Baird
Baird raised the firm’s price target on Climb Bio (CLYM) to $21 from $12 and keeps an Outperform rating on the shares. The firm updated its model following its R&D…
Climb Bio price target raised to $19 from $8 at BTIG
BTIG raised the firm’s price target on Climb Bio (CLYM) to $19 from $8 and keeps a Buy rating on the shares. The company’s anti-CD19 mAb has multiple near-term data…
Climb Bio Transcript: R&D Spotlight: Budoprutug and the CD19 Opportunity
Budoprutug is advancing in pMN, ITP, and SLE with robust early data, including durable remissions and strong B-cell depletion. Key 2026 data readouts will inform dose selection, clinical efficacy, and expansion plans, with subcutaneous formulation development enhancing market potential.
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast T...
Climb Bio initiated with a Buy at Chardan
Chardan initiated coverage of Climb Bio (CLYM) with a Buy rating and $22 price target The firm says the company is advancing two “differentiated” monoclonal antibodies targeting “validated but improva...
Climb Bio management to meet with Piper Sandler
Meeting to be held in Boston on April 30 hosted by Piper Sandler.
Climb Bio to sell 9.481M shares at $9.50 in private placement
Climb Bio (CLYM) announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate…
Climb Bio, Inc. Announces $110.0 Million Private Placement
WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...
Climb Bio price target raised to $18 from $10 at Oppenheimer
Oppenheimer analyst Leland Gershell raised the firm’s price target on Climb Bio (CLYM) to $18 from $10 and keeps an Outperform rating on the shares ahead of upcoming clinical reveals,…
Climb Bio initiated with an Outperform at Mizuho
Mizuho analyst Joseph Catanzaro initiated coverage of Climb Bio (CLYM) with an Outperform rating and $18 price target The company’s lead assets budoprutug and CLYM116 as positioned to establish a…
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...
Climb Bio granted Fast Track Designation to budoprutug by FDA
Climb Bio (CLYM) announced that the FDA has granted Fast Track Designation to budoprutug, the company’s investigational anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropat...
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to...
Climb Bio management to meet with Piper Sandler
Meeting to be held in New York on April 8 hosted by Piper Sandler.
Climb Bio initiated with a Buy at B. Riley
B. Riley initiated coverage of Climb Bio (CLYM) with a Buy rating and $26 price target The firm cites the company’s “robust execution” in early-stage trials of two antibodies developed…
Climb Bio initiated with a Buy at Truist
Truist initiated coverage of Climb Bio (CLYM) with a Buy rating and $17 price target Climb is advancing two clinical-stage assets with “validated mechanisms and blockbuster potential” in Budoprutug an...
Climb Bio initiated with a Strong Buy at Raymond James
Raymond James analyst Christopher Raymond initiated coverage of Climb Bio (CLYM) with a Strong Buy rating and $25 price target The company’s two lead assets – CLYM116 in development for…
Climb Bio price target raised to $15 from $11 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $15 from $11 and keeps a Buy rating on the shares following the Q4 report.
Climb Bio Transcript: Leerink Global Healthcare Conference 2026
A year of foundational execution sets up multiple data readouts in 2026 for two lead antibody programs targeting B-cell mediated diseases. Key differentiators include broader B-cell targeting, subcutaneous formulations, and a novel APRIL-only antibody, with strong financial runway and ongoing business development focus.